<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="306">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 14, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00299962</url>
  </required_header>
  <id_info>
    <org_study_id>803776</org_study_id>
    <secondary_id>P01CA066726</secondary_id>
    <nct_id>NCT00299962</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Pleural Malignancies</brief_title>
  <official_title>A Phase I Clinical Trial of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-beta (BG00001, Ad.hIFN-β for Pleural Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen Idec</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I study will evaluate the safety of two doses of BG00001 at different doses and
      intervals.  Eligible subjects will have:

        -  malignant pleural mesothelioma, or

        -  pleural effusions who have progressed through at least one prior therapy or have
           refused therapy

      BG00001 is given twice through a catheter in the pleural space.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ad.hIFN-β (BG00001) is a replication-defective recombinant adenoviral vector containing the
      human interferon-beta (hIFN-β) gene.  This Phase I study is designed to evaluate the safety
      and maximum tolerated dose (MTD) of two doses of intrapleural (IP) Ad.hIFN-β in subjects
      with pleural malignancies either metastatic or pleural mesothelioma.

      Five dose levels will be studied:

        -  Dose levels 1, 2, and 3 will be given on Days 1 and 15

        -  Dose levels 4 and 5 will be given on Days 1 and 8
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determine toxicity of two doses of intrapleural BG00001 (Ad.hIFN-β over 8 days, and</measure>
    <time_frame>Through Day 85</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess systemic and intrapleural cytokine responses as well as cellular and humoral immune responses after repeated BG00001 instillation,</measure>
    <time_frame>Through Day 85</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>and to assess, in a preliminary way, efficacy via tumor regression, time to progression and survival.</measure>
    <time_frame>15 years or until subject dies, whichever comes first</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Pleural Mesothelioma</condition>
  <condition>Metastatic Pleural Effusions</condition>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>on Days 1 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Days 1 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Days 1 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adenoviral-mediated Interferon-beta</intervention_name>
    <description>BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8</description>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <other_name>adenoviral-mediated Interferon-beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SCH 721015</intervention_name>
    <description>Comparison of different doses and frequency of investigational agent</description>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <other_name>Adenoviral-mediated Interferon-beta</other_name>
    <other_name>Ad.hIFN-beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must have malignant pleural effusion from mesothelioma or metastatic from primary
             lung, breast, gastrointestinal, genitourinary, melanoma, or sarcoma

          -  must have evaluable disease

          -  must have ECOG performance status of 2

          -  must have pleural space involved with tumor accessible for pleural catheter

          -  must have FEV1 &gt; 1 liter or 40% of predicted value

          -  must have completed radiotherapy and/or treatment with chemotherapy, cytotoxic, or
             immunologic agents 4 weeks prior to dosing with BG00001

          -  concurrent Tarceva is allowed if patients has been on a stable dose for at least
             three months and has not had serious adverse events

          -  patients on stable dose of hormone may continue use of hormone

          -  patients on stable dose of Tarceva for 3 months and without complications may remain
             on Tarceva

        Exclusion Criteria:

          -  malignant pleural effusions secondary to lymphoma

          -  rapidly re-accumulating, symptomatic malignant pleural effusions that require
             immediate mechanical or chemical pleurodesis for palliation

          -  untreated brain metastases

          -  use of concurrent systemic steroids or immunosuppressants
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel H. Sterman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.oncolink.upenn.edu/</url>
    <description>website University of Pennsylvania Abramson Cancer Center</description>
  </link>
  <link>
    <url>http://www.marf.org</url>
    <description>mesothelioma research foundation</description>
  </link>
  <verification_date>September 2010</verification_date>
  <lastchanged_date>September 29, 2010</lastchanged_date>
  <firstreceived_date>March 3, 2006</firstreceived_date>
  <responsible_party>
    <name_title>Daniel H. Sterman, M.D.</name_title>
    <organization>University of Pennsylvania</organization>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <keyword>immunotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
